prednisone and Lymphoma, B-Cell studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.

Research Excerpts

Excerpt	Relevance	Reference
" The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma."	9.14	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). ( Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G, 2009)
"In this pilot study, the authors assessed the feasibility of combination epratuzumab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)."	9.12	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. ( Ansell, SM; Colgan, JP; Dogan, A; Geyer, S; Habermann, TM; Inwards, DJ; Kahl, BS; Maurer, MJ; Micallef, IN; White, WL, 2006)
"Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied."	9.10	Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002)
"Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma immunophenotype."	7.88	Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma. ( Al-Nadaf, S; Burton, JH; Curran, KM; Rebhun, RB; Skorupski, KA; Venable, RO; Willcox, JL, 2018)
"Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy)."	7.85	Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results ( Alfò, M; Ansuinelli, M; Bracci, S; De Sanctis, V; Di Rocco, A; Grapulin, L; Martelli, M; Minniti, G; Moleti, ML; Musio, D; Osti, MF; Russo, E; Spagnoli, A; Tombolini, V; Valeriani, M, 2017)
"Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle."	7.81	Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. ( Back, AR; Lee, J; Phillips, JC; Schleis, SE; Smith, AN; Smrkovski, OA, 2015)
" We report the case of a patient with schizophrenia who developed B-cell lymphoma and was treated with chemotherapy consisting of CHOP regimen, rituximab, and methotrexate."	7.79	Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine. ( Borra, D; Denton, K; Kolli, V; Pulluri, M; Sharma, A, 2013)
"The 4-aminoquinolines, including chloroquine and hydroxychloroquine, have been successfully employed to treat patients with granuloma-forming disease-associated, vitamin D metabolite-mediated hypercalcemia."	7.70	Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. ( Adams, JS; Kantorovich, V, 1999)
"Bortezomib has demonstrated efficacy in patients with relapsed B-cell non-Hodgkin lymphoma (NHL) both alone and in combination with other agents; however, limited data exist regarding its toxicity in combination with common frontline therapies for indolent NHL."	6.77	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. ( Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M, 2012)
"Lamivudine (LAM) was administered orally from the start of R-CHOP."	5.34	[Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma]. ( Hayashi, T; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Matsunaga, T; Miyanishi, K; Niitsu, Y; Okuda, T; Ono, K; Sagawa, T; Sato, T; Sato, Y; Takada, K; Takimoto, R, 2007)
"Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL."	5.33	Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Best, JH; Hornberger, JC, 2005)
"Paraneoplastic pemphigus is a life-threatening autoimmune bullous disease associated with neoplasia, generally of lymphoid origin."	5.33	Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. ( Baradad, M; Herrero, C; Iranzo, P; Llambrich, A; Martínez De Pablo, MI; Mascaró, JM, 2005)
"R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard care for aggressive B-cell lymphoma."	5.19	Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. ( Bittenbring, J; Fleckenstein, J; Hänel, M; Held, G; Löffler, M; Murawski, N; Pfreundschuh, M; Pöschel, V; Rübe, C; Schmitz, N; Schubert, J; Wilhelm, S; Ziepert, M; Zwick, C, 2014)
"Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma."	5.15	Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. ( Ando, K; Hotta, T; Kinoshita, T; Maseki, N; Morishima, Y; Nawano, S; Ogura, M; Shibata, T; Suzuki, T; Takeuchi, K; Taniwaki, M; Terauchi, T; Tobinai, K; Tsukasaki, K; Uike, N; Watanabe, T; Yamaguchi, M, 2011)
" The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma."	5.14	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). ( Brice, P; Briere, J; Ertault, M; Ferme, C; Gisselbrecht, C; Golfier, JB; Haioun, C; Mounier, N; Ribrag, V; Salles, G, 2009)
"To evaluate the effect of rituximab in limited-stage diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter phase II trial combining rituximab with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) followed by involved-field radiation therapy (IFRT)."	5.13	Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. ( Fisher, RI; LeBlanc, M; McCarty, MJ; Miller, TP; Persky, DO; Rimsza, LM; Spier, CM; Stea, B; Unger, JM, 2008)
"The precise mechanism of rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is not fully elucidated."	5.12	FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. ( Do, YR; Hyun, MS; Jung, HD; Kim, DH; Kim, JG; Kim, MK; Lee, JJ; Park, YH; Shin, HJ; Sohn, SK; Yang, DH, 2006)
"The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined."	5.12	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. ( Corrado, C; Gill, D; Hansen, M; Imrie, K; Jaeger, U; Kuhnt, E; Kvaloy, S; Lehtinen, T; Loeffler, M; López-Guillermo, A; Ma, D; Mendila, M; Milpied, N; Osterborg, A; Pettengell, R; Pfreundschuh, M; Rashford, M; Scheliga, A; Shpilberg, O; Stahel, R; Trneny, M; Trümper, L; Walewski, J; Zinzani, PL, 2006)
"To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a two-stage randomized trial of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP (R-CHOP), with a second random assignment to maintenance rituximab (MR) or observation in responding patients."	5.12	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. ( Cassileth, PA; Cohn, JB; Dakhil, SR; Fisher, RI; Gascoyne, RD; Habermann, TM; Horning, SJ; Morrison, VA; Peterson, BA; Weller, EA; Woda, B, 2006)
"We aimed to define the role of cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) followed by involved field radiotherapy (IFRT) for treating localized primary gastric diffuse large B-cell lymphoma (DLBCL)."	5.12	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation. ( Ahn, YC; Bang, SM; Im, do H; Kang, JH; Kim, K; Kim, MS; Kim, WS; Ko, YH; Lee, J; Lee, SH; Lee, SS; Lim, DH; Park, K; Park, KW; Park, YH; Ryoo, BY; Yang, SH, 2006)
"In this pilot study, the authors assessed the feasibility of combination epratuzumab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)."	5.12	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. ( Ansell, SM; Colgan, JP; Dogan, A; Geyer, S; Habermann, TM; Inwards, DJ; Kahl, BS; Maurer, MJ; Micallef, IN; White, WL, 2006)
"To evaluate the effect of epirubicin on therapeutic response and survival in patients with indolent nonfollicular B-cell lymphomas (INFL) treated with pulsed high-dose chlorambucil."	5.10	Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. ( Baldini, L; Brugiatelli, M; Cavanna, L; Colombi, M; Federico, M; Gobbi, P; Goldaniga, M; Liberati, M; Lombardo, M; Luminari, S; Merli, F; Morabito, F; Sacchi, S; Silingardi, V; Stelitano, C, 2003)
"Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied."	5.10	Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002)
"The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)."	5.10	CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. ( Bouabdallah, R; Briere, J; Coiffier, B; Gaulard, P; Gisselbrecht, C; Herbrecht, R; Lederlin, P; Lepage, E; Morel, P; Reyes, F; Salles, G; Tilly, H; Van Den Neste, E, 2002)
"We hypothesized that incremental improvements in the cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy regimen through optimization of drug selection, schedule, and pharmacokinetics would improve outcome in patients with large B-cell lymphomas."	5.10	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. ( Balis, F; Chabner, BA; Cheson, BD; Cole, D; Drbohlav, N; Grossbard, ML; Gutierrez, M; Harris, N; Jaffe, ES; Janik, J; Little, RF; Longo, DL; Pearson, D; Pittaluga, S; Raffeld, M; Staudt, L; Steinberg, SM; Wilson, WH; Wittes, R, 2002)
"Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma."	4.91	A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. ( Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE, 2015)
"For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the gold standard for the treatment of aggressive lymphomas, 90% of which are diffuse, large B-cell lymphomas (DLBCLs)."	4.83	Rituximab for the treatment of diffuse large B-cell lymphomas. ( Held, G; Pfreundschuh, M; Pöschel, V, 2006)
"We report a case of B-cell lymphoma with the larynx as the primary site of presentation in a rheumatoid arthritis patient previously treated with methotrexate."	4.82	B-cell lymphoma of the larynx in a patient with rheumatoid arthritis. ( Freeland, AP; Patiar, S; Ramsden, JD, 2005)
"Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)."	4.12	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. ( Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L, 2022)
"Dose-adjusted (DA-) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) is a front-line treatment option for aggressive B-cell lymphomas."	4.02	Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. ( Kubal, TE; Li, W; McCarthy, KT; Richter, KA; Tobon, KA, 2021)
"Prior to the introduction of rituximab, primary mediastinal B-cell lymphoma (PMBCL) had high rates of treatment failure with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), prompting the use of consolidative mediastinal radiation or more intensive chemotherapy regimens."	3.91	R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. ( Ambinder, RF; Borowitz, MJ; Jones, RJ; Messmer, M; Shanbhag, SP; Swinnen, LJ; Tsai, HL; Varadhan, R; Wagner-Johnston, N, 2019)
" High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)."	3.88	Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. ( Bocchia, M; Cencini, E; Fabbri, A; Gentili, F; Mazzei, MA; Schiattone, L, 2018)
"A 55-year-old woman with concurrent active thyroid orbitopathy and B-cell lymphoma developed acute exacerbation of thyroid orbitopathy after receiving Rituximab, cyclophosphamide, hydroxydaunorubicin, Prednisone (R-CHOP) chemotherapy, presenting with subtotal loss of vision and severe eyelid edema."	3.88	Chemotherapy-induced exacerbations of thyroid orbitopathy in a patient with B-cell lymphoma. ( Croon-de Boer, F; Dalm, VASH; Liu, C; Paridaens, D; van Hagen, PM, 2018)
"Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma immunophenotype."	3.88	Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma. ( Al-Nadaf, S; Burton, JH; Curran, KM; Rebhun, RB; Skorupski, KA; Venable, RO; Willcox, JL, 2018)
"Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy)."	3.85	Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results ( Alfò, M; Ansuinelli, M; Bracci, S; De Sanctis, V; Di Rocco, A; Grapulin, L; Martelli, M; Minniti, G; Moleti, ML; Musio, D; Osti, MF; Russo, E; Spagnoli, A; Tombolini, V; Valeriani, M, 2017)
"Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle."	3.81	Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. ( Back, AR; Lee, J; Phillips, JC; Schleis, SE; Smith, AN; Smrkovski, OA, 2015)
"Clinical and/or biological risk factors are needed to identify elderly patients with aggressive B-cell lymphoma able to receive full-dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) treatment."	3.81	Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. ( Auberger, J; Boekstegers, A; Egle, A; Greil, R; Hopfinger, G; Hufnagl, C; Kemmerling, R; Melchardt, T; Morre, P; Neureiter, D; Pleyer, L; Steinkirchner, S; Weiss, L, 2015)
" We report the case of a patient with schizophrenia who developed B-cell lymphoma and was treated with chemotherapy consisting of CHOP regimen, rituximab, and methotrexate."	3.79	Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine. ( Borra, D; Denton, K; Kolli, V; Pulluri, M; Sharma, A, 2013)
" From these clinical and laboratory data, the patient was diagnosed as having B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS) and treated with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)."	3.78	[Adult T-cell leukemia-lymphoma developed from an HTLV-1 carrier during treatment of B-cell lymphoma-associated hemophagocytic syndrome]. ( Fujishima, N; Guo, YM; Hirokawa, M; Ito, M; Kameoka, Y; Nagao, T; Noguchi, S; Saitoh, H; Sawada, K; Tagawa, H; Takahashi, N; Watanabe, A, 2012)
"The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-cell lymphoma have recently been improved by the addition of rituximab and by increasing the dose density."	3.75	Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. ( Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Rodríguez Franco, C; Saura Grau, S, 2009)
" For acute myelogenous leukemia, cytarabine with anthracycline agent is believed to be the standard treatment in first remission induction therapy."	3.74	[The standard treatments for patients with hematological malignancies in Japan]. ( Ishizawa, K, 2007)
" To our knowledge, our patient is the first with NBS reported in the literature who was successfully treated for diffuse large B-cell lymphoma with the anti-CD20 monoclonal antibody rituximab in addition to a modified dose of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy."	3.74	Successful treatment of diffuse large B-cell non-hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome. ( Begovic, D; Dumic, M; Krnic, N; Kusec, R; Labar, B; Nola, M; Radman, I; Rados, M, 2007)
"For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL)."	3.73	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. ( Chhanabhai, M; Connors, JM; Donaldson, J; Fitzgerald, C; Gascoyne, RD; Gill, K; Klasa, R; MacPherson, N; O'Reilly, S; Sehn, LH; Spinelli, JJ; Sutherland, J; Wilson, KS, 2005)
" We report a 67-year-old man with B-cell lymphoma who developed hepatitis B reactivation following chemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab."	3.73	Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. ( Erb, SR; Ho, JK; Hoskins, PJ; Law, JK; Steinbrecher, UP; Yoshida, EM, 2005)
" Of 33 SL cases, 14 consecutive diffuse large B-cell lymphomas were treated with CHOP (adriamycin, cyclophosphamide, vincristine and prednisone) or CHOP-like chemotherapy regimen."	3.73	Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. ( Assaf, E; Azoulay, R; Bosq, J; Cainap, C; Jabbour, E; Koscielny, S; Lapusan, S; Oprea, C; Ribrag, V; Vanel, D, 2005)
"The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL)."	3.73	Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. ( Bang, YJ; Do, YR; Heo, DS; Kang, YK; Kim, DH; Kim, HJ; Kim, JK; Kim, SY; Kim, YK; Lee, JJ; Lee, KH; Lee, WS; Oh, SJ; Park, YH; Ryoo, BY; Ryu, MH; Sohn, SK; Song, HS; Suh, CW; Yang, SH, 2006)
" A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy."	3.73	Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. ( Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M, 2006)
"A 26-year-old woman, diagnosed with diffuse large B-cell lymphoma, was treated with CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, prednisone), rituximab and radiotherapy."	3.71	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. ( Brien, W; Crump, M; Mollee, P; Patterson, B; Song, KW, 2002)
"The 4-aminoquinolines, including chloroquine and hydroxychloroquine, have been successfully employed to treat patients with granuloma-forming disease-associated, vitamin D metabolite-mediated hypercalcemia."	3.70	Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. ( Adams, JS; Kantorovich, V, 1999)
" We report the pharmacokinetics (PK) and drug-drug interaction (DDI) for pola."	2.94	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ( Agarwal, P; Dere, RC; Girish, S; Jin, JY; Lee, C; Li, C; Li, X; Lu, D; Lu, T; Miles, D; Shemesh, CS, 2020)
"To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma."	2.82	[Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. ( Yang, YZ, 2016)
"To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP), in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL)."	2.82	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ( Ananthakrishnan, R; Boni, J; Crump, M; Davies, A; Hatake, K; Ishibashi, T; MacDonald, D; Ogura, M; Paccagnella, ML; Tobinai, K; Vandendries, E, 2016)
"LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas."	2.80	Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. ( Barboza, R; Coelho, BM; Guerra, JL; Lucas, SR; Maranhão, RC; Pozzi, DH, 2015)
"Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone."	2.79	Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. ( Anderson, JR; Barth, M; Cairo, MS; Frazer, JK; Galardy, P; Goldman, S; Gross, TG; Harrison, L; Perkins, SL; Sanger, W; Shiramizu, B; Smith, L; Weinstein, H, 2014)
"Bortezomib has demonstrated efficacy in patients with relapsed B-cell non-Hodgkin lymphoma (NHL) both alone and in combination with other agents; however, limited data exist regarding its toxicity in combination with common frontline therapies for indolent NHL."	2.77	A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. ( Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M, 2012)
" We carried out a pilot pharmacokinetic study in 10 patients with B-cell non-Hodgkin lymphoma treated with rituximab associated with chemotherapy on a three-weekly basis."	2.74	Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. ( Blasco, H; Chatelut, E; Congy-Jolivet, N; de Bretagne, IB; Le Guellec, C, 2009)
" Severe adverse events occurred on 12 occasions (4% of cycles), involving 11 patients (22% of total); the most frequent severe adverse event was interstitial pneumonia which occurred in seven patients (14% of total)."	2.72	Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. ( Brusamolino, E; Fava, S; Gargantini, L; Lazzarino, M; Montalbetti, L; Morra, E; Pagnucco, G; Pascutto, C; Pinotti, G; Rigacci, L; Rusconi, C; Uziel, L, 2006)
" Long-term administration of G-CSF appears to influence the survival rate by reducing immunosuppressive IL-12 p40 production."	2.72	Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients. ( Asaka, M; Fukuhara, T; Hashino, S; Imamura, M; Kakinoki, Y; Kasai, M; Kawamura, T; Kobayashi, H; Kondo, T; Kunieda, Y; Kurosawa, M; Masauzi, N; Morioka, M; Ota, S; Shono, Y; Tanaka, J; Toubai, T, 2006)
" PL-doxorubicin 30 mg/m2, was given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses."	2.72	CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Battista, M; Battista, R; Cabras, MG; Fabbri, A; Fanin, R; Gallamini, A; Lenoci, M; Molinari, AL; Tomadini, V; Zaccaria, A; Zaja, F, 2006)
"CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years."	2.71	Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). ( Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A, 2003)
"The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL)."	2.71	Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. ( Czuczman, M; Fisher, RI; Grillo-Lopez, A; Grossbard, ML; Link, BK; Vose, JM, 2005)
"Here, we present two follicular lymphoma patients; one transformed to THL, another transformed to DHL."	2.49	Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review. ( Sun, B; Wang, Y; Xu, X; Zhang, L; Zhang, Q; Zhang, Y, 2013)
"For the management of multiple myeloma, high-dose chemotherapy, mainly melphalan with autologous stem cell transplantation, has become the standard treatment even for elderly patients less than 65 years of age."	2.44	[Hematological malignancies]. ( Usui, N, 2007)
"By contrast, B-cell lymphoblastic lymphoma/leukemia is a rare high-grade malignancy that comprises approximately 10% of all lymphoblastic lymphomas."	2.44	Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature. ( Cox, DP; Dong, R; Jordan, RC; Treseler, P, 2007)
"Erythema nodosum is the most frequent clinicopathological variant of the panniculitides."	2.42	[Erythema nodosum association with malignant lymphoma]. ( Griniūte, R; Pileckyte, M, 2003)
"Disease progression was significantly more frequent in patients presenting an immunological event or an M component."	2.41	Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. ( Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C, 2002)
"Low-grade and follicular lymphomas account for approximately 40% of the incidences of NHL in the United States."	2.41	Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. ( Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D, 2002)
"In gastric MALT lymphoma, Helicobacter pylori might provide the antigenic stimulus for its growth."	2.40	[Recent progress in the management of malignant lymphoma]. ( Ohnishi, K, 1997)
"However, some patients may develop interstitial pneumonitis (IP), which can be caused by various factors; one of the most important factors is Pneumocystis jirovecii."	1.91	Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis. ( Jin, J; Liu, C; Mai, W; Mao, L; Meng, H; Qian, J; Tong, H; Wei, J; Yang, C; Yang, M; Ye, X; Yu, W; Zhang, X; Zhu, Y, 2023)
"To study if obesity is a risk factor in elderly patients (>60 years) with aggressive B-cell lymphoma, the outcomes of 576 elderly patients treated with rituximab in the RICOVER-60 trial were analysed in a retrospective study with regard to body mass index (BMI) and gender."	1.48	Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( Altmann, B; Hohloch, K; Loeffler, M; Pfreundschuh, M; Schmitz, N; Trümper, L; Zettl, F; Ziepert, M, 2018)
"Precursor B-cell lymphoblastic lymphoma arising from the ovary is extremely rare and to our knowledge, only 5 cases have been reported in the literature."	1.46	Lymphoblastic Lymphoma Presenting as Bilateral Ovarian Mass in an Adolescent Girl. ( Narayanan, G; Soman, LV, 2017)
"(2) Burkitt's lymphoma was the most common (34/43, 79."	1.43	[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia]. ( Gao, J; Guo, J; Guo, X; Jia, CS; Li, Q; Zhou, CY; Zhu, YP, 2016)
"The incidence of infections over the 2-year period was 16."	1.43	Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma. ( Ando, M; Ando, Y; Emi, N; Hayashi, T; Inaguma, Y; Ito, K; Kakumae, Y; Okamoto, A; Okamoto, M; Tomono, A; Tsuge, M; Yamada, S, 2016)
"Under a diagnosis of testicular cancer from manipulation test and ultrasonography, high orchiectomy was performed."	1.42	[Primary testicular malignant lymphoma in a hemodialysis patient : a case report]. ( Hamao, T; Nakatsuji, H; Sakaki, M, 2015)
"Interestingly, in chronic lymphocytic leukemia (CLL) patients, we found that the patients with β2-microglobulin (β2-MG) < 3."	1.42	Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. ( Feng, X; Gu, Z; Li, F; Li, Z; Liu, W; Qi, J; Qiu, L; Xu, Y; Yi, S; Yu, Z; Zhan, F; Zou, D, 2015)
" This study aimed to assess the efficacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients."	1.42	Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. ( Gui, L; Han, X; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Yao, J; Zhang, C; Zhang, S; Zhao, L; Zhou, P; Zhou, S, 2015)
" There was no statistically significant difference regarding number of rituximab courses or cumulative rituximab dosage between episodes with and without infections, respectively."	1.40	The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. ( Brade, J; Buchheidt, D; Hofmann, WK; Hummel, M; Kruth, J; Nissen, JC; Reinwald, M, 2014)
"Lymphoma-associated hemophagocytic syndrome (LAHS) is a life-threatening disorder, and LAHS secondary to B-cell lymphoma is relatively rare compared to that secondary to T- or NK/T-cell lymphoma in Western countries."	1.39	Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation. ( Fukayama, M; Kurokawa, M; Maeda, D; Maki, H; Nakamura, F; Nakazaki, K; Uni, M; Yoshimi, A, 2013)
"Acquired ichthyosis is a rare condition that can reveal an unsuspected haematological malignancy, thus allowing early diagnosis and management."	1.38	[Acquired ichthyosis and haematological malignancies: five cases]. ( Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ, 2012)
" Longer incubation period of blood culture is needed to detect the microbe and long-term use of antimicrobials is required to prevent recurrent cellulitis."	1.38	[Recurrent cellulitis due to Helicobacter cinaedi after chemotherapy for malignant lymphoma]. ( Ishizawa, J; Iwata, S; Matsuki, E; Mori, T; Murata, M; Okamoto, S; Shimizu, T; Sugita, K; Tsukada, Y; Yokoyama, K, 2012)
"Thus, the patient's progressive myelopathy was probably caused by IVLBCL invasion."	1.37	[A case of intravascular large B-cell lymphoma associated with transverse myelopathy]. ( Harigae, H; Seki, M; Sugawara, T; Takahashi, T; Yamamoto, K, 2011)
"One showed only skin involvement with panniculitis-like induration and responded well to therapy with Rituximab-CHOP (Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone)."	1.35	[Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease]. ( Ganser, A; Gutzmer, R; Kapp, A; Kofahl-Krause, D; Satzger, I; Völker, B, 2009)
"We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution."	1.34	Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. ( Fosså, A; Gaustad, P; Holte, H; Kolstad, A; Lauritzsen, GF; Torfoss, D, 2007)
"We report a case of acrodermatitis paraneoplastica successfully treated with PUVA therapy."	1.34	Acrodermatitis paraneoplastica responding to topical PUVA treatment. ( Abrou, AE; Hope, J; Jackson-Richards, D; Lim, HW; Ozog, DM, 2007)
"The dose-dense CHOP-14 regimen is efficient and safe in elderly patients with diffuse large B-cell lymphoma (DLBCL)."	1.34	Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. ( de Nully Brown, P; Hansen, M; Jurlander, J; Tholstrup, D, 2007)
"Lamivudine (LAM) was administered orally from the start of R-CHOP."	1.34	[Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma]. ( Hayashi, T; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Matsunaga, T; Miyanishi, K; Niitsu, Y; Okuda, T; Ono, K; Sagawa, T; Sato, T; Sato, Y; Takada, K; Takimoto, R, 2007)
"Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL."	1.33	Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Best, JH; Hornberger, JC, 2005)
"Adult rhabdomyoma is a rare mesenchymal tumor, which generally grows slowly and is mainly localized in the head and neck area."	1.33	Cervical adult rhabdomyoma presenting as a rapidly growing mass in a patient with diffuse large B-cell non-Hodgkin's lymphoma. ( Burg, JE; Hansen, T; Kirkpatrick, CJ; Koutsimpelas, D; Mann, WJ, 2005)
"Paraneoplastic pemphigus is a life-threatening autoimmune bullous disease associated with neoplasia, generally of lymphoid origin."	1.33	Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. ( Baradad, M; Herrero, C; Iranzo, P; Llambrich, A; Martínez De Pablo, MI; Mascaró, JM, 2005)
"Two of the patients died of disease progression."	1.33	Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. ( Ishikura, S; Kitadai, Y; Kobayashi, Y; Matsuno, Y; Mera, K; Nakamura, S; Ochiai, A; Oda, I; Ohtsu, A; Suzumiya, J; Tobinai, K; Yokoi, T; Yoshino, T, 2006)
"Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course."	1.32	A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003)
"The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has improved since the era of highly active antiretroviral therapy, but median survival remains low."	1.32	Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. ( Franchini, G; Grant, N; Gutierrez, M; Jaffe, ES; Kavlick, MF; Little, RF; Mitsuya, H; Pittaluga, S; Raffeld, M; Shearer, G; Steinberg, SM; Wilson, WH; Yarchoan, R, 2003)
"Grade 3-4 leukopenia was observed in 61% of patients with 11% of febrile neutropenia."	1.32	ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma. ( Cavalli, F; Cocorocchio, E; Conconi, A; De Luzio, K; Ferrucci, PF; Martinelli, G; Mazzetta, C; Mingrone, W; Peccatori, FA; Santoro, P; Zucca, E, 2003)
"A diagnosis of seronegative Wegener's granulomatosis was made and the patient received a combination of prednisone and cyclophosphamide with clinical improvement and clearance of the radiological lesions in the lungs."	1.32	Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis. ( Amariglio, N; Amir, G; Cohen, Y; Polliack, A; Schibi, G, 2004)
"We report a case of chronic intestinal schistosomiasis presenting in a previously asymptomatic 34-year-old woman from Saudi Arabia with large B cell lymphoma."	1.32	Symptoms of intestinal schistosomiasis presenting during treatment of large B cell lymphoma. ( Kontoyiannis, DP; Montes, M; White, AC, 2004)
"Records of 75 patients with aggressive B-NHL,received infusions of 375 mg/m(2) of rituximab combined with or without chemotherapy in our center,have been retrospectively analyzed."	1.32	[Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Lin, TY; Sun, XF; Xia, ZJ; Zhang, HY; Zhang, L, 2004)
"The histopathological diagnosis was renal cell carcinoma."	1.31	[Renal cell carcinoma in a patient with malignant lymphoma: a case report]. ( Senda, M; Takagi, Y; Tanaka, J, 2000)
"Precursor B cell lymphoblastic lymphoma has not been previously reported as a form of posttransplant lymphoproliferative disease."	1.31	Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease. ( Borges, E; Ferry, JA; Friedmann, AM, 2002)
"The clinical course of follicular lymphoma (FL) is well known."	1.31	Successful treatment of gastrointestinal follicular lymphoma with rituxan and combination chemotherapy. ( Al-Salman, J; Boonswang, P; Salib, H, 2001)
" One exception might be CBCC patients who were younger (median age 56 years) and who were usually in good general condition so that they might qualify for high dosage chemotherapy and stem cell support."	1.30	Outcome of patients with low-grade B cell non-Hodgkin lymphoma and initial bone marrow involvement: data of a single institution. ( Heinz, R; Hopfinger, G; Tüchler, H, 1997)
"Dantrolene and azumolene were potent inducers of cell death in both systems reducing the viable cell count by 70-90% in comparison with normal controls."	1.30	In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low-grade non-Hodgkin's lymphoma. ( Davies, DC; Joel, S; Lister, TA; Salam, AH; Shamash, J; Williams, A, 1998)
"Cervical phlegmona is a rare occurrence associated with infections of the ENT region."	1.29	[Rare complications of soft tissue infections in the head and neck area: deep neck phlegmona, thrombophlebitis and mediastinitis with pericardial effusion]. ( Gutmann, R; Wustrow, TP, 1994)
"In November 1991, recurrence was found in the peripheral lymph node and the colon."	1.29	[Successful oral administration of etoposide therapy for refractory malignant lymphoma treated with frequent combination chemotherapy]. ( Ashida, T; Ayabe, T; Maekawa, I; Namiki, M; Shibata, Y; Taruishi, M, 1993)

Research

Studies (677)

Authors

Clinical Trials (41)

Trial Overview

Trial Outcomes

Progression-free Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	95 (14.03)	18.2507
2000's	369 (54.51)	29.6817
2010's	177 (26.14)	24.3611
2020's	36 (5.32)	2.80

Authors	Studies
Knörr, F	1
Zimmermann, M	2
Attarbaschi, A	1
Kabíčková, E	1
Maecker-Kolhoff, B	1
Ruf, S	1
Kühnle, I	1
Ebinger, M	1
Garthe, AK	1
Simonitsch-Klupp, I	1
Oschlies, I	2
Klapper, W	4
Burkhardt, B	2
Woessmann, W	1
Freitas, AC	1
Carvalho, IP	1
Esteves, S	1
Salgado, L	1
Gomes da Silva, M	1
Shimizu, N	1
Ngayama, D	1
Watanabe, Y	1
Yamaguchi, T	1
Nakamura, S	3
Ohira, M	1
Saiki, A	1
Onda, H	1
Yamaoka, S	1
Abe, K	1
Nakaseko, C	1
Tatsuno, I	1
Dunleavy, K	4
Funakoshi, Y	1
Yakushijin, K	2
Ohji, G	1
Hojo, W	1
Sakai, H	2
Watanabe, M	5
Saeki, M	1
Hirakawa, Y	1
Sakai, R	1
Matsumoto, S	1
Mizutani, Y	1
Kitao, A	1
Miyata, Y	1
Saito, Y	1
Kawamoto, S	1
Yamamoto, K	3
Ito, M	3
Nishimura, M	1
Imamura, Y	1
Kiyota, N	1
Matsuoka, H	1
Mori, Y	1
Minami, H	1
Ou, W	1
Jiang, T	1
Tang, X	1
Fujishita, K	1
Yasuhisa, S	1
Oka, S	1
Fujisawa, Y	1
Machida, T	1
Imai, T	1
Lakhotia, R	1
Melani, C	2
Roschewski, M	3
Wilson, WH	8
Schep, D	1
Van Koughnett, JA	1
Velker, V	1
Correa, RJM	1
Ferreri, AJM	1
Angelillo, P	1
Erbella, F	1
Cattaneo, C	1
Verga, L	1
Lleshi, A	1
Allione, B	1
Ponzoni, M	2
Facchetti, F	1
Pagani, C	1
Foppoli, M	1
Pecciarini, L	1
Sassone, M	1
Steffanoni, S	1
Flospergher, E	1
Rossi, G	2
Spina, M	2
Re, A	1
Lian, K	3
Zhang, QH	3
Hou, SL	3
Li, L	6
Bewarder, M	2
Kaddu-Mulindwa, D	2
Kos, IA	1
Lesan, V	1
Held, G	6
Poeschel, V	3
Thurner, L	1
Bittenbring, JT	2
Schmitz, N	14
Truemper, L	3
Pfreundschuh, M	21
Christofyllakis, K	1
Loeffler, M	13
Altmann, B	3
Ziepert, M	10
Belia, M	1
Drandakis, I	1
Lakiotaki, E	1
Arapaki, M	1
Panitsas, F	1
Triantafyllou, EF	1
Plata, E	1
Siakantaris, MP	1
Angelopoulou, MK	1
Korkolopoulou, P	1
Vassilakopoulos, TP	1
Liu, C	3
Zhang, X	1
Zhu, Y	1
Wei, J	1
Ye, X	1
Yang, C	1
Tong, H	1
Mai, W	1
Yang, M	1
Qian, J	1
Mao, L	1
Meng, H	1
Jin, J	2
Yu, W	1
Malachowski, SJ	1
Sun, J	1
Chen, PL	1
Seminario-Vidal, L	1
Ivanick, NM	1
Moh, M	1
Seeley, EJ	1
Benn, BS	1
Walewski, J	4
Wolf-Ringwall, A	1
Lopez, L	1
Elmslie, R	1
Fowler, B	1
Lori, J	1
Sfiligoi, G	1
Skope, A	1
Arnold, E	1
Hughes, KL	1
Thamm, DH	1
Ehrhart, EJ	1
Avery, AC	2
Lana, SE	1
Craig, KKL	1
Wood, GA	1
Keller, SM	1
Mutsaers, AJ	1
Wood, RD	1
Olszewski, AJ	3
Butera, JN	1
Reagan, JL	2
Castillo, JJ	2
Mussolin, L	2
Lovisa, F	1
Gallingani, I	1
Cavallaro, E	1
Carraro, E	1
Damanti, CC	1
Vinti, L	1
Sala, A	1
Micalizzi, C	1
Santoro, N	1
Piglione, M	1
Cellini, M	1
Buffardi, S	1
Buldini, B	1
D'Amore, ESG	1
Biffi, A	1
Pillon, M	1
Shemesh, CS	1
Agarwal, P	1
Lu, T	1
Lee, C	1
Dere, RC	1
Li, X	2
Li, C	2
Jin, JY	1
Girish, S	1
Miles, D	1
Lu, D	1
Frosch, ZAK	1
Landsburg, DJ	6
Kimura, M	1
Fujiwara, S	1
Tanaka, A	1
Omura, Y	1
Yamashita, D	1
Hinoda, T	1
Sakai, N	1
Kohara, N	1
Kopel, J	1
Swarup, K	1
Thein, K	1
Swarup, S	1
Roider, T	1
Wang, X	3
Hüttl, K	1
Müller-Tidow, C	2
Rosenwald, A	2
Stewart, JP	1
de Castro, DG	1
Dreger, P	1
Hermine, O	1
Kluin-Nelemans, HC	2
Grabe, N	1
Dreyling, M	3
Pott, C	1
Ott, G	1
Hoster, E	1
Dietrich, S	1
Méhes, G	1
Matolay, O	1
Beke, L	1
Czenke, M	1
Pórszász, R	1
Mikó, E	1
Bai, P	1
Berényi, E	1
Trencsényi, G	1
Lu, F	2
Lei, T	1
Yu, H	1
Chen, X	1
Peng, S	1
Han, S	1
Yang, H	1
Koike, A	1
Nasta, SD	3
Svoboda, J	5
Schuster, SJ	4
Wasik, MA	1
Caponetti, GC	1
Schmitz, C	2
Rekowski, J	2
Müller, SP	2
Farsijani, N	1
Hertenstein, B	2
Franzius, C	2
von Verschuer, U	1
La Rosée, P	2
Freesmeyer, M	2
Wilop, S	2
Krohn, T	2
Raghavachar, A	2
Ganser, A	3
Bengel, FM	2
Prange-Krex, G	2
Kroschinsky, F	2
Kotzerke, J	2
Giagounidis, A	2
Dührsen, U	3
Hüttmann, A	2
Rosolowski, M	1
Regitz, E	1
Assmann, G	1
Li, W	2
Richter, KA	1
Tobon, KA	1
McCarthy, KT	1
Kubal, TE	1
Zettl, F	2
Zeynalova, S	3
Pöschel, V	3
Hohloch, K	2
Wulf, GG	2
Glass, B	7
Trümper, L	8
Casadei, B	1
Argnani, L	1
Morigi, A	1
Lolli, G	1
Broccoli, A	1
Pellegrini, C	1
Nanni, L	1
Stefoni, V	2
Coppola, PE	1
Carella, M	1
Cavo, M	1
Zinzani, PL	7
Uchida, E	1
Lei, MM	1
Roeland, E	1
Lou, U	1
Mitobe, M	1
Kawamoto, K	1
Suzuki, T	4
Suwabe, T	1
Shibasaki, Y	1
Masuko, M	1
Inoue, K	1
Miyoshi, H	1
Ohshima, K	1
Sone, H	1
Takizawa, J	1
Benjamin, SE	1
Sorenmo, KU	1
Krick, EL	1
Salah, P	1
Walsh, KA	1
Weinstein, NM	1
Keuler, NS	1
Atherton, MJ	1
Lenz, JA	1
Appio, L	1
Landoni, C	1
La Targia, M	1
Bertolli, V	1
Chiarucci, M	1
Crovetti, G	1
Vassenna, E	1
Serio, G	1
Bregni, M	1
Hahn, J	1
Friebe-Hoffmann, U	1
Bischof, F	1
Falkiewicz, MK	2
Maly, J	1
Blum, KA	2
Howlett, C	1
Feldman, T	1
Mato, AR	2
Hill, BT	1
Li, S	3
Medeiros, LJ	5
Torka, P	1
Hernandez-Ilizaliturri, F	2
Reddy, NM	2
Singavi, A	1
Fenske, TS	4
Chavez, JC	2
Kaplan, JB	1
Behdad, A	2
Petrich, AM	3
Bast, MA	2
Vose, JM	6
Costa, C	1
Lansigan, F	1
Gerson, JN	1
Barta, SK	1
Calzada, O	2
Cohen, JB	2
Lue, JK	1
Amengual, JE	1
Rivera, X	1
Persky, DO	3
Peace, DJ	1
Nathan, S	1
Cassaday, RD	2
Lamos, C	1
Dippel, E	1
Cencini, E	2
Fabbri, A	4
Schiattone, L	1
Gentili, F	1
Mazzei, MA	1
Bocchia, M	2
Dohm, AJ	1
Truemper, LH	1
Bleckmann, A	1
Shah, NN	3
Szabo, A	1
Huntington, SF	1
Epperla, N	1
Reddy, N	1
Ganguly, S	1
Vose, J	1
Obiozor, C	1
Faruqi, F	1
Kovach, AE	1
Costa, LJ	1
Xavier, AC	1
Okal, R	1
Kanate, AS	1
Ghosh, N	1
Kharfan-Dabaja, MA	1
Strelec, L	1
Hamadani, M	2
Chavez, J	1
Dalm, VASH	1
van Hagen, PM	1
Croon-de Boer, F	1
Paridaens, D	1
Nijland, M	2
van Meerten, T	1
Seitz, A	1
Huls, G	1
Kibbelaar, R	1
Visser, L	1
van den Berg, A	1
Diepstra, A	1
Song, YH	1
Zhong, MZ	1
Chai, Q	1
Gong, KY	1
Tan, XL	1
Hu, JY	1
Wang, GH	1
Liu, DL	1
Wang, B	1
Zhu, YD	1
Yan, F	1
Adams, T	1
Fuchs, D	1
Shadoan, PK	1
Johnstone, L	1
Lau, BM	1
McGhan, L	1
Anwer, F	1
Al-Kateb, H	1
Hamzaoui, L	1
Medhioub, M	1
Khsiba, A	1
Mahmoudi, M	1
Badri, T	1
Azouz, MM	1
Maas, C	1
Lüftinger, R	1
Krois, W	1
Matthes-Martin, S	1
Bayer, G	1
Boztug, K	1
Metzelder, M	1
Ambrosio, MR	1
Lazzi, S	2
Bello, GL	1
Santi, R	1
Porro, LD	1
de Santi, MM	1
Guazzo, R	1
Mundo, L	1
Rigacci, L	3
Kovalchuck, S	1
Onyango, N	1
Zaja, F	2
Angrilli, F	1
Stelitano, C	4
Cabras, MG	3
Spataro, G	1
Bob, R	1
Menter, T	1
Granai, M	1
Cevenini, G	1
Naresh, KN	1
Stein, H	1
Sabattini, E	2
Leoncini, L	2
Cherng, HJ	1
Sargent, RL	1
Schrank-Hacker, A	1
Morrissette, JJD	1
Iemura, T	1
Oba, A	1
Matsui, M	1
Mano, C	1
Kawabata, N	1
Horisawa, Y	1
Miyahara, Y	1
Itoh, M	1
Abid, MB	1
Wang, S	1
Loi, HY	1
Chan, EHL	1
Poon, LM	1
de Mel, S	1
Al-Nadaf, S	1
Rebhun, RB	1
Curran, KM	1
Venable, RO	1
Skorupski, KA	1
Willcox, JL	1
Burton, JH	1
Ennishi, D	1
Jiang, A	1
Boyle, M	1
Collinge, B	1
Grande, BM	1
Ben-Neriah, S	1
Rushton, C	1
Tang, J	1
Thomas, N	1
Slack, GW	2
Farinha, P	1
Takata, K	1
Miyata-Takata, T	1
Craig, J	1
Mottok, A	1
Meissner, B	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS[NCT04181489]	Phase 2	55 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Year[NCT00052936]	Phase 3	1,506 participants (Actual)	Interventional	2001-01-31	Completed
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma[NCT00001337]	Phase 2	348 participants (Actual)	Interventional	1993-05-08	Active, not recruiting
Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II[NCT00070018]	Phase 2	46 participants (Actual)	Interventional	2004-02-29	Completed
AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA[NCT01055496]	Phase 1	103 participants (Actual)	Interventional	2010-03-31	Completed
A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma[NCT00049036]	Phase 2	106 participants (Actual)	Interventional	2003-03-31	Completed
Rituximab + Standard CHOP (R･S-CHOP) vs Rituximab+ Bi-weekly CHOP (R･Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)[NCT00147121]	Phase 2/Phase 3	300 participants (Actual)	Interventional	2002-09-30	Completed
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas[NCT00634179]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2008-02-29	Completed
Prospective Multicenters Clinical Cohort Study on Efficacy and Safety of Stratified Treatment for Chinese Children With Burkitt Lymphoma/Diffuse Large B-cell Lymphoma[NCT03958916]		500 participants (Anticipated)	Observational [Patient Registry]	2017-05-05	Recruiting
Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China[NCT02405676]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258]	Phase 4	50 participants (Anticipated)	Interventional	2006-10-31	Completed
Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell[NCT02916316]		127 participants (Actual)	Observational	2014-02-12	Active, not recruiting
Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.[NCT00144755]	Phase 3	600 participants (Actual)	Interventional	2003-12-31	Completed
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497]	Phase 1	10 participants (Actual)	Interventional	2017-09-05	Active, not recruiting
Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467]	Phase 2	150 participants (Actual)	Interventional	2006-08-31	Active, not recruiting
Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.[NCT00429065]		30 participants	Observational	2007-01-31	Recruiting
Analysis of E4494 Tissues to Determine the Prognostic Significance of Biomarkers in Diffuse Large B Cell Lymphoma (DLBCL) Treated With Standard Chemotherapy (CHOP) Plus Rituximab ®)1[NCT00898157]		1,600 participants (Actual)	Observational	2007-09-24	Completed
Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma[NCT00003150]	Phase 3	630 participants (Anticipated)	Interventional	1997-12-31	Completed
Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab[NCT00064116]	Phase 3	824 participants (Actual)	Interventional	2001-05-08	Completed
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989]	Phase 4	32 participants (Anticipated)	Interventional	2023-02-28	Recruiting
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352]	Phase 2	22 participants (Actual)	Interventional	2012-10-31	Completed
Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Random[NCT02428751]	Phase 3	216 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma[NCT00301821]	Phase 2	107 participants (Actual)	Interventional	2006-01-31	Completed
FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study[NCT00002757]	Phase 3	1,148 participants (Actual)	Interventional	2001-06-30	Completed
A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044]	Phase 3	408 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin's Lymphoma[NCT00005089]	Phase 2	71 participants (Actual)	Interventional	2000-04-30	Completed
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.[NCT03964480]		1,000 participants (Anticipated)	Observational [Patient Registry]	2018-10-14	Recruiting
Phase II Study of the Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma[NCT00169468]	Phase 2	48 participants (Actual)	Interventional	2005-01-31	Completed
A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000]	Phase 3	226 participants (Anticipated)	Interventional	2017-07-26	Recruiting
Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma[NCT00135499]	Phase 3	138 participants (Actual)	Interventional	2001-10-16	Terminated (stopped due to Recruitment too low)
Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995]	Phase 3	481 participants (Actual)	Interventional	2003-06-30	Completed
Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation[NCT00169195]	Phase 2	49 participants (Actual)	Interventional	2003-04-30	Completed
Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis[NCT00261118]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2004-04-30	Completed
Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma[NCT02767674]	Phase 3	258 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941]		52 participants (Actual)	Interventional	2005-02-28	Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma[NCT01415765]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2011-07-15	Withdrawn
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610]	Phase 2	78 participants (Actual)	Interventional	2011-11-30	Active, not recruiting
A Prospective, Single-arm, Open-label, Phase 2 Study to Evaluate Efficacy and Safety of DA-EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis[NCT01818908]	Phase 2	50 participants (Anticipated)	Interventional	2012-06-30	Active, not recruiting
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185]	Phase 2	36 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma[NCT03018626]	Phase 3	402 participants (Anticipated)	Interventional	2017-07-27	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Measured from date of registration to date of first observation of progression or symptomatic deterioration. Progression is defined as one or more of the following must occur. Unequivocal progression of disease in the opinion of the treating physician (an explanation must be provided). Appearance of a new lesion/site. Death due to disease without documented progression or symptomatic deterioration. Symptomatic deterioration is defined as global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00070018)
Timeframe: at 6 weeks after treatment, then every 6 months for 2 years, then annually thereafter

Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts

Intervention	percentage of participants (Number)
CHOP + RT + Zevalin	89

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period

Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts

Intervention	Months (Median)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	NA
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	NA

Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts

Intervention	Months (Median)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	NA
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	NA

PFS was defined as time from date of first dose to the earlier date of progression (including symptomatic deterioration), date of death from any cause, or initiation of new anticancer therapy for the lymphoma. Participants without an event were censored at the date of the last valid tumour assessment. A valid tumour assessment visit was defined as the tumour assessment visit with OR of CR, PR, SD, or PD, but not 'Not Done' or 'Unknown'. Participants without a post-baseline tumour assessment and without a PFS event were censored on the date of first dose. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks

Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts

Intervention	Months (Median)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	14.36
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	6.14

PFS was defined as time from date of first dose to the earlier date of progression (including symptomatic deterioration), date of death from any cause, or initiation of new anticancer therapy for the lymphoma. Participants without an event were censored at the date of the last valid tumour assessment. A valid tumour assessment visit was defined as the tumour assessment visit with overall response of CR, PR, stable disease (SD), or disease progression (PD), but not 'Not Done' or 'Unknown'. Participants without a post-baseline tumour assessment and without a PFS event were censored on the date of first dose. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks

Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2

Intervention	Months (Median)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	16.36
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	10.12

DLT was defined as: febrile neutropenia, Grade (Gr) 4 neutropenia ≥7 days, Gr 4 thrombocytopenia ≥7 days, Gr 3/4 thrombocytopenia associated with bleeding requiring a transfusion, Gr 3/4 non-hematologic toxicity (except alopecia) ≥7 days or treatment-related and clinically significant irrespective of duration, ≥Gr 3 QTc prolongation, Gr 4 alanine or aspartate aminotransferase, Gr 2 hyperbilirubinemia (greater than (>)1.5 x upper normal limit) >7 days, delayed recovery from a treatment-related toxicity that prevented re-dosing by >7 days, or Granulocyte-colony stimulating factor treatment during the first cycle. (NCT01055496)
Timeframe: From the first dose of study medication (Study Day 1) to the completion of the first 21-day cycle.

Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1

Intervention	Participants (Count of Participants)
Cohort 1, Arm 2	0
Cohort 2a, Arm 2	2
Cohort 2b, Arm 2	1
Cohort 3b, Arm 2	2
Cohort 4, Arm 2	0
MTD Confirmation Cohort, Arm 2	3

Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts

Intervention	Participants (Count of Participants)
Cohort 1, Arm 1	0
Cohort 2, Arm 1	0
Cohort 3, Arm 1	1
Cohort 4, Arm 1	2
MTD Confirmation Cohort, Arm 1	2

OR was evaluated according to the International Response Criteria for NHLs. CR was defined as complete disappearance of all lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their GTD for nodes >1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the SPD of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or GTD (for single nodules). With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks.

Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy

Intervention	Percentage of participants (Number)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	81.3
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	51.9

"The following parameters were analyzed for blood chemistry: blood urea nitrogen (or urea), creatinine, glucose, calcium, sodium, potassium, phosphorus, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, total bilirubin (and direct bilirubin, if total bilirubin was elevated), alkaline phosphatase, uric acid (or urate), albumin and total protein. Laboratory test results were graded using the NCI CTCAE v3.0 where CTCAE Grade 3 equals severe and CTCAE Grade 4 equals life threatening or disabling." (NCT01055496)
Timeframe: Within 3 days prior to the start of each cycle, on Day 8 of each cycle, on Day 15 of Cycles 1, 2, and 3, and the end-of-treatment visit. Each Cycle is 21 Days.

Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy

Intervention	Percentage of Participants (Number)
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin	21.3
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin	36.4

"The following parameters were analyzed for hematology: lymphocytes, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, monocytes, neutrophils, platelets, prothrombin international normalized ratio, prothrombin time, fibrinogen, and activated partial thromboplastin time. Laboratory test results were graded using the NCI CTCAE v3.0 where CTCAE Grade 3 equals severe and CTCAE Grade 4 equals life threatening or disabling." (NCT01055496)
Timeframe: Within 3 days prior to the start of each cycle, Day 8 of each cycle, Day 15 of Cycles 1, 2, and 3, and the end-of-treatment visit. Each Cycle is 21 Days.

Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts

Intervention	Percentage of Participants (Number)
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin	91.7
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin	96.4

OR was evaluated according to the International Response Criteria for NHLs. CR was defined as complete disappearance of all lesions and disease-related symptoms; all nodes must have decreased to normal (less than or equal to [≤]1.5 centimeters [cm] in their greatest transverse diameter (GTD) for nodes >1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the sum of the product diameters (SPD) of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or GTD (for single nodules). With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks.

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts

Intervention	Percentage of participants (Number)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	81.3
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	53.6

Measure includes death from any cause, PD (including symptomatic deterioration) during and after treatment or initiation of new anticancer therapy for the lymphoma. PD was defined as symptomatic deterioration and according to the International Response Criteria for NHL: 1) appearance of any new lesion >1.5 cm in any axis during or at EOT, even if other lesions are decreasing, 2) at least a 50% increase from nadir in the SPD of any previously involved or single involved nodes, or the size of other lesions (splenic or hepatic). Lymph nodes with a short axis diameter of <1.0 cm must increase by ≥50% and to a size of 1.5x1.5 cm or >1.5 cm in the long axis, 3) 50% increase in the longest diameter of any single previously identified node >1 cm in its short axis. PD was defined as clinical PD, new non-nodal lesions or new nodal lesion ≥1.5 cm in GTD, progression of existing non-index lesions or bone marrow that was negative and now positive. (NCT01055496)
Timeframe: 6, 12 and 24 months

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	80.00	66.67	22.22
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	60.98	47.92	33.54

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	61.85	51.54	44.67
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	54.74	24.88	NA

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: 6, 12, and 24 months

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	100.00	80.00	80.00
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	74.07	62.96	55.09

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: 6, 12, and 24 Months

Mean Inotuzumab Ozogamicin Serum Concentrations

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	84.38	78.13	71.61
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	88.00	59.11	53.74

Pharmacokinetic (PK) samples were required for participants enrolled in the confirmatory and preliminary efficacy MTD cohorts only (Parts 2 and 3). Concentrations of inotuzumab ozogamicin in serum were determined using appropriate, validated unconjugated (also known as free) bioanalytical assays. (NCT01055496)
Timeframe: Pre-dose on Cycle 1, Day 2; Pre-dose, 1 and 3 hours post-dose on Cycle 3, Day 2; 24 hours post-dose on Cycle 3, Day 3 and 168 hours post-dose on Cycle 3, Day 8.

Mean Inotuzumab Ozogamicin Serum Concentrations

Intervention	ng/mL (Mean)
	Cycle 1 Day 2, 0h
Cohort 1, Arm 2	NA
Cohort 3b, Arm 2	NA
Cohort 4, Arm 1	NA
Cohort 4, Arm 2	NA

Percentage of Participants With a Treatment Emergent AE

Intervention	ng/mL (Mean)
	Cycle 1 Day 2, 0h	Cycle 3 Day 2, 0h	Cycle 3 Day 2, 1h	Cycle 3 Day 2, 3h	Cycle 3 Day 3, 24h	Cycle 3 Day 8, 168h
Cohort 2b/MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	NA	25.00	283.27	280.33	154.25	NA
Cohort 3/MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	NA	NA	189.74	213.95	110.39	NA

An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event may not necessarily have had a causal relationship with the treatment or usage. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as those occurring on or after the first study drug dose day through and including 56 days post last dose of study drug. The severity of all AEs was graded by the investigator using the National Cancer Institute Common Terminology Criteria for AE Version 3.0 (NCI CTCAE v3.0). (NCT01055496)
Timeframe: SAEs were assessed from informed consent through and including the end of treatment visit (at least 28 calendar days after last study drug administration). Non-SAEs were recorded from time of the first dose of study drug through last participant visit.

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Intervention	Percentage of Participants (Number)
	Subjects with AEs	Subjects with SAEs	Subjects with Grade 3 or 4 AEs	Subjects with Grade 5 AEs	Subjects discontinued due to AEs	Subjects with dose reduced due to AEs	Subjects with temporary discontinuation due to AEs
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin	100	31.3	89.6	4.2	27.1	16.7	54.2
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin	100	45.5	96.4	5.5	36.4	32.7	67.3

Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

Intervention	proportion (Number)
EPOCH + Concurrent Rituximab	0.69
EPOCH Followed by Rituximab	0.53

INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Intervention	mg/m^2 (Number)
MTD of Bortezomib With Vincristine Capped at 1.5 mg	1.62

Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years

Duration of Response

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)	Overall Response Rate (ORR)
Phase I: Induction	13	6	19
Phase II: Maintenance	19	10	29

Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months

Number of Patients With a Complete Response

Intervention	months (Median)
Bendamustine/Ofatumumab	5.6

Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months

Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety

Intervention	Participants (Count of Participants)
Bendamustine/Ofatumumab	7

A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks

Overall Response (OR)

Intervention	Participants (Count of Participants)
Bendamustine/Ofatumumab	16

Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months

Overall Survival (OS)

Intervention	Participants (Count of Participants)
Bendamustine/Ofatumumab	19

Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months

Progression-free Survival

Intervention	months (Median)
Bendamustine/Ofatumumab	12.0

Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months

Time to Progression (TTP)

Intervention	months (Median)
Bendamustine/Ofatumumab	8.6

Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months

Event-free Survival After 12 Months

Intervention	months (Median)
Bendamustine/Ofatumumab	10.5

The primary endpoint of the trial was the percentage of the eligible patients who were alive and event-free 12 months after enrollment to the study (EFS12). (NCT00301821)
Timeframe: From Baseline to 12 months

Overall Response Rate (ORR)

Intervention	percentage of participants (Number)
Epratuzumab + Rituximab + CHOP	78

Overall response rate will be estimated by the number of patients with objective status of partial response (PR), unconfirmed complete response (CRu), or complete response (CR) during the first 6 cycles of treatment divided by number of evaluable patients (met eligibility criteria, signed consent form, and started treatment). Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: Baseline to first 6 cycles of treatment

Overall Survival

Intervention	percentage of participants (Number)
Epratuzumab + Rituximab + CHOP	95

Percentage of participants alive at different time points (NCT00301821)
Timeframe: time from study entry to 36 months

Progression-free Survival (PFS)

Intervention	percentage of Participants (Number)
	Overall Survival at 12 months	Overall Survival at 24 months	Overall Survival at 36 months
Epratuzumab + Rituximab + CHOP	89	81	80

Percentage of participants Progression-free at different time points. Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: the time from study entry to 36 months

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	percentage of participants (Number)
	Progression Free Survival at 12 months	Progression Free Survival at 24 months	Progression Free Survival at 36 months
Epratuzumab + Rituximab + CHOP	85	77	76

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Article	Year
Double-hit lymphoma: optimizing therapy. Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Management; Doxorubicin; H	2021
BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis. Journal of chemotherapy (Florence, Italy), 2023, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide;	2023
Diagnosis and Management of Cutaneous B-Cell Lymphomas. Dermatologic clinics, 2019, Volume: 37, Issue:4 Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; An	2019
Aggressive B-cell lymphoma: chasing the target. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2020, Volume: 68, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin;	2020
Primary B Cell Lymphoma of the Pancreas. Journal of gastrointestinal cancer, 2020, Volume: 51, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Magnetic Resonance;	2020
[Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017, Volume: 68, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2017
Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis. British journal of haematology, 2019, Volume: 186, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Chlorambu	2019
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. Current hematologic malignancy reports, 2019, Volume: 14, Issue:4 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha	2019
Pixantrone beyond monotherapy: a review. Annals of hematology, 2019, Volume: 98, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines	2019
Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review. International journal of clinical and experimental pathology, 2013, Volume: 6, Issue:4 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell	2013
Ovarian ALK+ diffuse large B-cell lymphoma: a case report and a review of the literature. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2013, Volume: 32, Issue:5 Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor	2013
The aggressive peripheral T-cell lymphomas: 2013. American journal of hematology, 2013, Volume: 88, Issue:10 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival	2013
Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-CHOP therapy and intrathecal administration: a case report and review of literature. International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:6 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla	2014
In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma. Expert opinion on drug delivery, 2014, Volume: 11, Issue:12 Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyc	2014
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine	2015
Primary mediastinal large B-cell lymphoma. Critical reviews in oncology/hematology, 2008, Volume: 68, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin	2008
Intravascular large B-cell lymphoma associated with t(14;19)(q32;q13) translocation. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:18 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes,	2011
Lymphoma study group of JCOG. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother	2012
Autologous or allogeneic transplantation in B- and T-cell lymphomas. Best practice & research. Clinical haematology, 2012, Volume: 25, Issue:1 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo	2012
Anti-CD20 antibody therapy for B-cell lymphomas. The New England journal of medicine, 2012, May-24, Volume: 366, Issue:21 Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combin	2012
Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clinic proceedings, 2012, Volume: 87, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi	2012
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. The Cochrane database of systematic reviews, 2012, Sep-12, Issue:9 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamusti	2012
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clinical lymphoma, 2002, Volume: 3, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin	2002
Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 2 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot	2003
[Radiation therapy of localized diffuse large B-cell lymphoma]. Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 2003, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub	2003
[Erythema nodosum association with malignant lymphoma]. Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Diagnosis, Dif	2003
Primary breast lymphoma. Leukemia & lymphoma, 2003, Volume: 44, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis	2003
T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leukemia research, 2004, Volume: 28, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Mar	2004
Primary adrenal lymphoma presenting as adrenal insufficiency. A case report and review of literature. Connecticut medicine, 2004, Volume: 68, Issue:1 Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal	2004
[Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2004, Volume: 101, Issue:2 Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Child; Cli	2004
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. International journal of radiation oncology, biology, physics, 2004, Aug-01, Volume: 59, Issue:5 Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy	2004
Reduced-intensity conditioning and blood stem cell transplantation from an HLA-identical sibling for severe aplastic anaemia: two patients with successful engraftment but a fatal post-transplant lymphoproliferative disorder in the other. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:5 Topics: Adrenal Cortex Hormones; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Diabetes Mellitus, Ty	2004
[New antibodies in cancer treatment]. Praxis, 2004, Sep-22, Volume: 93, Issue:39 Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti	2004
[A case report of unresectable mesenteric malignant lymphoma with long survival]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2004, Volume: 101, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide;	2004
Primary lymphoma of the cervix uteri: a diagnostic challenge. Report of two cases and review of the literature. European journal of gynaecological oncology, 2005, Volume: 26, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diagnosis, Diffe	2005
Primary non-Hodgkin's lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature. Breast cancer (Tokyo, Japan), 2005, Volume: 12, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cy	2005
ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Polish journal of pathology : official journal of the Polish Society of Pathologists, 2005, Volume: 56, Issue:1 Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclo	2005
Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Do	2005
The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free	2005
Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy	2005
B-cell lymphoma of the larynx in a patient with rheumatoid arthritis. The Journal of laryngology and otology, 2005, Volume: 119, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; C	2005
[Primary central nervous system lymphoma--a report of 32 cases with literature review]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chi	2006
Fourth biannual report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy	2006
[Gastric lyphoma - still a result of surgery?]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2006, Volume: 77, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti	2006
Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gene Expression Regul	2006
Rituximab for the treatment of diffuse large B-cell lymphomas. Expert review of anticancer therapy, 2006, Volume: 6, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti	2006
Standard treatment of advanced-stage diffuse large B-cell lymphoma. Seminars in hematology, 2006, Volume: 43, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived	2006
Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Seminars in hematology, 2006, Volume: 43, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy	2006
Treatment of diffuse large B-cell lymphoma: a risk-based approach. Clinical lymphoma & myeloma, 2006, Volume: 7 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti	2006
Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. Journal of surgical oncology, 2006, Dec-15, Volume: 94, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; C	2006
[Hematological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3 Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl	2007
Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:6 Topics: 12E7 Antigen; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cell Adh	2007
Diffuse large B-cell lymphoma. Seminars in radiation oncology, 2007, Volume: 17, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti	2007
[A case of retroperitoneal NHL with direct invasion to the liver, pancreas and gastric wall]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1995, Volume: 92, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Dru	1995
[Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature]. Bulletin du cancer, 1994, Volume: 81, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C	1994
Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Bailliere's clinical haematology, 1994, Volume: 7, Issue:2 Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Ly	1994
[Recent progress in the treatment of malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub	1994
Primary lymphoma of the pericardium: report on a "cured" case and review of the literature. Medical and pediatric oncology, 1994, Volume: 22, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Heart Neoplasms; Humans; Lymphoma,	1994
[Chemotherapy for malignant lymphoma in Western countries and Japan]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials,	1993
[Homogeneous clinical behavior of a group of cutaneous B-cell lymphomas]. Sangre, 1995, Volume: 40, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th	1995
[Metastatic malignant melanoma in treated non-Hodgkin's lymphoma]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1996, Volume: 47, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Lymph Nodes; Lymphatic	1996
[Recent progress in the management of malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin	1997
Primary non-Hodgkin's lymphoma of the common bile duct. The American journal of gastroenterology, 1997, Volume: 92, Issue:9 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon	1997
[Diagnosis and therapy of malignant thyroid lymphoma]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1997, Jul-10, Volume: 86, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytodia	1997
[From Hashimoto thyroiditis to B-cell lymphoma of the thyroid gland]. Schweizerische medizinische Wochenschrift, 1999, Jun-12, Volume: 129, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin;	1999
[Primary non-Hodgkin lymphoma of the mandible--a case report]. Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia, 1999, Volume: 109, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Cyclophosp	1999
[New combination therapies in hematological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy	2000
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy	2002
[Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplas	2002
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. The hematology journal : the official journal of the European Haematology Association, 2001, Volume: 2, Issue:3 Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin;	2001
[Digestive lymphomatous polyposis]. Gastroenterologie clinique et biologique, 1992, Volume: 16, Issue:8-9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Gastrointesti	1992
[Massive bilateral non-Hodgkin's lymphoma of the adrenal glands]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1990, Volume: 31, Issue:9 Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide	1990

Intervention	Days (Median)
	Progression Free Survival	Overall Survival
DRBEAT Regimen	132	564

Authors	Studies
Knörr, F	1
Zimmermann, M	2
Attarbaschi, A	1
Kabíčková, E	1
Maecker-Kolhoff, B	1
Ruf, S	1
Kühnle, I	1
Ebinger, M	1
Garthe, AK	1
Simonitsch-Klupp, I	1
Oschlies, I	2
Klapper, W	4
Burkhardt, B	2
Woessmann, W	1
Freitas, AC	1
Carvalho, IP	1
Esteves, S	1
Salgado, L	1
Gomes da Silva, M	1
Shimizu, N	1
Ngayama, D	1
Watanabe, Y	1
Yamaguchi, T	1
Nakamura, S	3
Ohira, M	1
Saiki, A	1
Onda, H	1
Yamaoka, S	1
Abe, K	1
Nakaseko, C	1
Tatsuno, I	1
Dunleavy, K	4
Funakoshi, Y	1
Yakushijin, K	2
Ohji, G	1
Hojo, W	1
Sakai, H	2
Watanabe, M	5
Saeki, M	1
Hirakawa, Y	1

prednisone and Lymphoma, B-Cell

Research Excerpts

Research

Studies (677)

Authors

Clinical Trials (41)

Trial Overview

Trial Outcomes

Progression-free Survival

Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts

Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts

Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts

Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts

Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2

Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1

Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts

Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy

Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy

Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts

Mean Inotuzumab Ozogamicin Serum Concentrations

Mean Inotuzumab Ozogamicin Serum Concentrations

Percentage of Participants With a Treatment Emergent AE

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Duration of Response

Number of Patients With a Complete Response

Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety

Overall Response (OR)

Overall Survival (OS)

Progression-free Survival

Time to Progression (TTP)

Event-free Survival After 12 Months

Overall Response Rate (ORR)

Overall Survival

Progression-free Survival (PFS)

Safest Dose of Temozolomide for the DRBEAT Regimen

One-year Progression-free Survival and Overall Survival

Reviews

Trials

Other Studies